Researchers studied national hospitalization data to identify patients diagnosed with S. aureus infections from 2010 through 2014. They analyzed treatment costs in aggregate and by three infection types: S. aureus blood stream infections, S. aureus pneumonia infections and other S. aureus infections.
The study shows, contrary to previous research, MRSA is not more expensive to treat than MSSA. After controlling for differences in patient populations, researchers found costs for the two were similar; however, skin and soft tissue MSSA infections were more expensive.
Additionally, the study shows MRSA patients face higher mortality rates than MSSA patients.
More articles on healthcare quality:
Viewpoint: Transparency on care quality, cost can revolutionize healthcare
Washington nurse accused of infecting patients with hep C loses nursing license, claims she ‘did not do this’
10 new genetic tests entering market daily, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.